This review highlights cellular therapies' potential to improve outcomes in patients with severe autoimmune rheumatic disease, suggesting future directions for research.
Collectively, these findings position cellular therapies as powerful, potentially transformative options for highly selected patients with severe, refractory lupus and autoimmune rheumatic disease, but also underscore the need for disciplined trial design, long-term safety surveillance, and strategies to ensure equitable access.
No takes yet. Share an insight, caveat, or question.
Koumpouras et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: